|
Company Information
Regenics AS, is a Norwegian biotechnology company based in Oslo. The business concept is to develop and patent technologies and products for therapeutic wound healing and cosmeceutical applications.
Regenics' proprietary technology is a revolutionary approach to skin regeneration, with power to improve wound healing, stimulate keratinocytes and fibroblasts, regulate skin cell differentiation and stimulate collagen secretion – technologies of benefit both in wound healing and cosmetic applications.
Regenics’ products aim to locally revive the regenerative abilities of skin cells in order to improve wound healing and skin cell proliferation with technologies utilize nature's own ingredients and healing processes to repair tissues by improving cell function and growth.
Regenics follows a proactive research and patent filing strategy to protect its novel technology and to ensure that it has a clear intellectual property path for marketing the product.
Regenics’ innovations include products from biomarine ingredients, including salmon eggs, with unique effects including improved wound healing, regeneration of skin cells, regulation of skin cell differentiation and increased collagen secretion. The transdifferentiation technology was developed by one of the founding partners in Regenics, Dr. Philippe Collas. Dr. Collas is one of the most successful and prolific researchers in the area of cell reprogramming. No product regulating the differentiation state of skin cells currently exists on the market, making Regenics’ product strategy unique. The outstanding scientific team and wide network of international collaborations with academic and industry leaders make Regenics capable of world-class research.
|
|
Scientific Team
President: Runhild Gammelsæter PhD, Born 1976.
runhild@regenics.no
 Dr. Gammelsæter holds a Ph.D. in cell physiology from the Faculty of Medicine of the University of Oslo. Working in the Neurotransmitter lab of the Centre of Molecular Biology and Neuroscience at the University of Oslo, she has previously investigated the physiology and cellular signaling of insulin-producing pancreatic islet. She is also well-versed in the area of nuclear and cell reprogramming. As a Fulbright scholar, Dr. Gammelsæter conducted research and held guest lectures at Joslin Diabetes Center of Harvard (Boston, MA, USA), UCSF (San Francisco, CA, USA) and Virginia Commonwealth University (Richmond, VA, USA). Additionally, she has studied psychology at the University of Oslo and the University of Washington, has completed courses in leadership, psychology and science journalism
Selected publications by dr. Gammelsæter:
1. "Complementary expression of SN1 and SAT2 in the islets of Langerhans suggests concerted action of glutamine transport in the regulation of insulin secretion."
2. "The components required for amino acid neurotransmitter signaling are present in adipose tissues."
3. "Novel approaches to epigenetic reprogramming of somatic cells."
4. "Glycine, GABA and their transporters in pancreatic islets of Langerhans: evidence for a paracrine transmitter interplay."
CSO: Mats Grände PhD, Born 1975.
mats@regenics.no
 Dr. Grände performed his PhD in Cell Biology at the Department of Anatomy and Cell Biology, Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden, where he studied classical cadherins in organ development and epithelial differentiation in the thyroid. Dr, Grände has long experience with cell-breeding and cell differentiation. For the last years he has been engaged as a Post-doc at the Institute of Biomedicine, Department of Medical Genetics, Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden developing a cell based assay system designed to be used in a high throughput drug screen, in cooperation with a major pharmaceutical company. He has also completed courses in Marketing Management, Economics and Organizational Behavior at MBA level.
Selected publications by dr. Grände:
1. "Genetic deletion of sonic hedgehog causes hemiagenesis and ectopic development of the thyroid in mouse."
2. "Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes."
Scientist: Christoffer Lund PhD, Born 1978.
christoffer@regenics.no
 Dr. C. Lund has specialized in proteomics and embryonal differentiation. His science work at the department of Basic Sciences and Aquatic Medicine, Norwegian School of Veterinary Sciences (NVH), Oslo, was focused on molecular and cellular mechanisms of neurodegenerative prion diseases, especially on the cellular trafficking and proteolytic processing of prion protein in cell culture. He has also been engaged as a scientist at NVH, working with methodological development of cultivation of embryonal stem cells from Zebrafish, and characterization of the differentiation of these.
Selected publications by Dr. C. Lund:
1. "Alternative translation initiation generates cytoplasmic sheep prion protein."
2. "Characterization of the prion protein 3F4 epitope and its use as a molecular tag."
3. "Proteolytic processing of the ovine prion protein in cell cultures."
|
Management Team
Chairman of the Board: Tore Rasmussen MBA, Born 1961.
 Mr. Rasmussen serves on the Regenics Board of Directors and has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen is the board chairman of Natural ASA, GenTel Bio Inc. and brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an M.B.A. degree from the University of Michigan, Ann Arbor, MI, USA, and serves as business advisor for Regenics.
Director, Scientific Advisor: Philippe Collas PhD, Born 1965.
 Dr. Collas serves on the Regenics Board of Directors. He is Professor at the Institute of Medical Biochemistry of the University of Oslo, Norway, where he directs a laboratory of 20 people. Dr. Collas holds an engineering degree from France and a PhD from the University of Massachusetts. He has tremendous experience in research on nuclear reprogramming from academia (University of Massachusetts, Amherst College, University of Oslo) and industry in the United States. He was a co-founder of Nucleotech LLC (USA) and has served as Consultant for several Biotech Companies in Europe, United States and Australia. He has developed cell-free systems to investigate nuclear dynamics and gene function and has published over 90 scientific articles in the area of nuclear reprogramming. He was the first to show that somatic cells can be reprogrammed using cellular extracts. Dr. Collas is member of the Norwegian Academy of Science and Letters.
Selected publications by dr. Collas:
1. "Fast genomic muChIP-chip from 1,000 cells."
2. "Epigenetic states in stem cells."
Director: Jan Remmereit Dipl. FGA, born 1958.
 Mr. Remmereit serves on the Regenics Board of Directors and is an investor in the Life Sciences field. Mr Remmereit is a true inventor and founder of several technology leading ventures in the Life Sciences area prior to co-founding Regenics. Examples are Natural ASA in Norway and GenTel Bio, Inc. in the United States. Mr. Remmereit has a Diploma FGA degree from the Gemmological Association of Great Britain. Mr. Remmereit also serves as IPR advisor to Regenics.
|
